Primera Biosystems Inc. landed $1.15 million in a debt financing round, according to a filing with the federal Securities and Exchange Commission.
The Mansfield, Mass.-based molecular diagnostics maker, which is developing a nucleic acid analysis system it calls Scalable Target Amplification Routine — STAR — last raised $21 million in a Series B equity round early last year.
The technology is a bench-top system offering “the best features of quantitative real-time [polymerase chain reaction] with true multiplexing of 60 or more targets,” according to the company’s website.